The operations for the administration of the third dose of the anti Covid vaccine, in the province of Arezzo, could start as early as next week. “We are working in this direction – explains the doctor Anna Beltrano, responsible for the vaccination campaign – in these days we have already organized organizational meetings, the control room is ready to get going. If there are no particular unforeseen events already from next week we will be able to start with the recalls. Extremely fragile patients will be contacted first. ”
And therefore the territory, in perfect line with what was established by the Ministry of Health in the circular on the administration of additional doses and “boosters”, is ready to get to work for the third step of the vaccination campaign. In all they will be ten categories of patients who will receive it as a priority, starting from transplanted and cancer patients.
Additional dose and booster dose
As reported in the circular of the ministry, it distinguishes the two categories. There additional dose it is the one that will be foreseen for subjects who will need an additional dose to complete the primary vaccination cycle of 2 doses, to achieve an adequate level of immune response. It will be administered at least later 28 days from the second, and as soon as possible if this period of time has already elapsed.
An additional dose is expected to be administered at least 28 days after the last dose:
- solid organ transplant recipients in immunosuppressive therapy;
- hematopoietic stem cell transplantation;
- waiting for organ transplant;
- T cell therapies;
- oncological pathology;
- primary immunodeficiencies (eg DiGeorge syndrome, Wiskott-Aldrich syndrome, common variable immunodeficiency etc.);
- secondary immunodeficiencies (eg: high-dose corticosteroid therapy over time, immunosuppressive drugs, biological drugs with significant impact on the functionality of the immune system, etc.);
- dialysis and severe chronic renal failure;
- previous splenectomy;
For these subjects the Pfizer vaccine will be used over the age of 12, and Moderna over the age of 18 (based on Aifa assessments)
The dose “booster” it counts on a reference audience without particularly fragile subjects. Instead, it is intended for “Populations characterized by a high risk, due to fragile conditions associated with the development of serious or even fatal disease, or due to occupational exposure”. The booster dose will be given at least 6 months after the last injection. However, this group will be better defined later: the circular explicitly clarifies that “at the moment, according to the indications of the CTS, the administration of the additional dose is considered a priority in transplanted and immunocompromised subjects”.